James C. Wernz

703 total citations
11 papers, 561 citations indexed

About

James C. Wernz is a scholar working on Oncology, Pathology and Forensic Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James C. Wernz has authored 11 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James C. Wernz's work include Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Chemotherapy-related skin toxicity (3 papers). James C. Wernz is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Chemotherapy-related skin toxicity (3 papers). James C. Wernz collaborates with scholars based in United States, Australia and Poland. James C. Wernz's co-authors include Craig E. Metroka, Susan E. Krown, Franco M. Muggia, James L. Speyer, Ronald H. Blum, Neil Dubin, Frederick Feit, Cynthia R. Ward, Anne Zeleniuch‐Jacquotte and Victor J. Ferrans and has published in prestigious journals such as New England Journal of Medicine, Urology and Cancer Chemotherapy and Pharmacology.

In The Last Decade

James C. Wernz

11 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James C. Wernz United States	9	370	232	147	98	61	11	561
Jones Se United States	13	166 0.4×	65 0.3×	195 1.3×	89 0.9×	17 0.3×	34	443
Bruna Angelelli Italy	14	313 0.8×	103 0.4×	48 0.3×	145 1.5×	24 0.4×	27	609
Brian Bird Ireland	11	279 0.8×	150 0.6×	65 0.4×	106 1.1×	15 0.2×	37	536
M. Varini Switzerland	11	319 0.9×	49 0.2×	240 1.6×	184 1.9×	15 0.2×	18	646
Marcella Occelli Italy	15	353 1.0×	226 1.0×	46 0.3×	176 1.8×	13 0.2×	29	691
Y. Kenis Belgium	12	238 0.6×	68 0.3×	65 0.4×	190 1.9×	9 0.1×	59	503
Dianne M. Howser United States	9	175 0.5×	50 0.2×	158 1.1×	64 0.7×	9 0.1×	12	491
B Kabakow United States	15	243 0.7×	42 0.2×	147 1.0×	88 0.9×	13 0.2×	47	734
Vishram B. Rege United States	14	484 1.3×	36 0.2×	77 0.5×	449 4.6×	25 0.4×	19	827
Metter Ge United States	9	261 0.7×	97 0.4×	127 0.9×	53 0.5×	4 0.1×	13	538

Countries citing papers authored by James C. Wernz

Since Specialization

Citations

This map shows the geographic impact of James C. Wernz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Wernz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Wernz more than expected).

Fields of papers citing papers by James C. Wernz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James C. Wernz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Wernz. The network helps show where James C. Wernz may publish in the future.

Co-authorship network of co-authors of James C. Wernz

This figure shows the co-authorship network connecting the top 25 collaborators of James C. Wernz. A scholar is included among the top collaborators of James C. Wernz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James C. Wernz. James C. Wernz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Wernz, James C.. (1996). Liposomal Drug Targeting in the Treatment of Kaposi's Sarcoma. . .. AIDS Patient Care and STDs. 10(6). 362–367. 1 indexed citations

Höchster, Howard S., Michael Green, Leonard Liebes, et al.. (1990). Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): A phase I study with pharmacology. Cancer Chemotherapy and Pharmacology. 26(4). 297–300. 9 indexed citations

Green, Michael D., et al.. (1990). Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. Investigational New Drugs. 8(3). 333–336. 1 indexed citations

Krown, Susan E., Craig E. Metroka, & James C. Wernz. (1989). Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria. 173 indexed citations

Colombo, Nicoletta, James L. Speyer, Michael R. Green, et al.. (1989). Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemotherapy and Pharmacology. 23(5). 323–328. 14 indexed citations

Speyer, James L., Michael D. Green, E Douglas Kramer, et al.. (1988). Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer. New England Journal of Medicine. 319(12). 745–752. 281 indexed citations

Speyer, James L., Howard S. Höchster, Leonard Liebes, et al.. (1988). Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon.. PubMed. 48(9). 2574–8. 9 indexed citations

Piccart, M., James L. Speyer, James C. Wernz, et al.. (1987). Advanced ovarian cancer: Three-year results of a 6–8 month, 2-drug cisplatin-containing regimen. European Journal of Cancer and Clinical Oncology. 23(6). 631–641. 19 indexed citations

Höchster, Howard S., Michael D. Green, Ronald H. Blum, et al.. (1986). Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial. Investigational New Drugs. 4(3). 275–278. 8 indexed citations

10.

Wernz, James C., et al.. (1985). Carcinomatous meningitis from transitional cell carcinoma of bladder. Urology. 25(5). 520–521. 25 indexed citations

11.

Spiegel, Robert J., Ronald H. Blum, Mark Levin, et al.. (1982). Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.. PubMed. 42(1). 354–8. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact